within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD24_SitagliptinAndErtugliflozin;

model SitagliptinAndErtugliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD24;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sitagliptin and ertugliflozin is a fixed-dose combination oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor while ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The combination provides glycemic control through complementary mechanisms. The combination is approved and marketed in various countries for adult patients with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects following oral administration. No published combined PK model for this exact fixed-dose combination, values are based on individual published PK properties of sitagliptin and ertugliflozin single agents.</p><h4>References</h4><ol><li><p>Qiu, X, et al., &amp; Xu, RA (2019). UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma. <i>Analytical biochemistry</i> 567 112–116. DOI:<a href=&quot;https://doi.org/10.1016/j.ab.2018.12.016&quot;>10.1016/j.ab.2018.12.016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30578763/&quot;>https://pubmed.ncbi.nlm.nih.gov/30578763</a></p></li><li><p>Fediuk, DJ, et al., &amp; Sahasrabudhe, V (2020). Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. <i>Clinical pharmacokinetics</i> 59(8) 949–965. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00875-1&quot;>10.1007/s40262-020-00875-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32337660/&quot;>https://pubmed.ncbi.nlm.nih.gov/32337660</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end SitagliptinAndErtugliflozin;
